03 apr: Nykredit Realkredit A/S - optagelse til handel og officiel noteri..
03 apr: Meddelelse vedrørende The Drilling Company of 1972 A/S og A.P. Mø..
03-04-2019 09:54:36

Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2019

Company Release no. 06/2019

To: NASDAQ Copenhagen A/S                                                      

Copenhagen, Denmark, 03 April 2019

 

Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2019

 

Summary: At Veloxis Pharmaceuticals A/S’ Annual General Meeting held earlier today, all proposals from the Board of Directors were adopted, including approval of the Annual Report.

At the General Meeting, the report by the Board of Directors and Executive Management was acknowledged and the audited Annual Report was approved.

It was decided that the previous year’s net loss of USD 5.285 million is carried forward by transfer to accumulated deficit.

All members of the Board of Directors were re-elected. Hence, the Board of Directors comprises:

  • Michael Thomas Heffernan
  • Mette Kirstine Agger
  • Anders Götzsche
  • Robert Samuel Radie
  • Lars Kåre Viksmoen
  • Paul Kevin Wotton

Subsequent to the Annual General Meeting, the Board of Directors constituted itself with Michael Thomas Heffernan as Chairman of the Board of Directors and Mette Kirstine Agger as Deputy Chairman of the Board of Directors.

Anders Götzsche will be Chairman and Mette Kirstine Agger and Robert Samuel Radie will be members of the Audit Committee. Michael Thomas Heffernan will be Chairman and Lars Kåre Viksmoen will be member of the Nomination Committee. Paul Kevin Wotton will be Chairman and Michael Thomas Heffernan and Mette Kirstine Agger will be members of the Remuneration Committee.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.

The proposed fee to the Board of Directors for the financial year 2019 was approved, and consequently the Board of Directors receives the following in 2019:

Remuneration to the Board of Directors

and board sub-committees (USD)

2019

Chairman of the Board of Directors100,000
Members of the Board of Directors50,000
Chairman of the Audit Committee20,000
Members of the Audit Committee10,000
Chairman of the Remuneration Committee15,000
Members of the Remuneration Committee7,500
Chairman of the Nomination Committee10,000
Members of the Nomination Committee5,000

Further, members of the Board of Directors may receive incentive-based remuneration under the Company's general guidelines for incentive-based remuneration to members of the Board of Directors and Executive Management, ref. Article 16 of the Articles of Association. Each board member will be granted warrants equal to the value of USD 150,000 calculated at the share price on the day of grant.

The proposal by the Board of Directors to authorize the Board of Directors to issue warrants was adopted by the General Meeting, and this resolution was incorporated as Article 5F in the Company's Articles of Association. In accordance therewith the Board of Directors is until 03 April 2024 authorized, at one or more times, to issue up to 17,000,000 warrants, each conferring a right to subscribe for 1 share of nominal DKK 0.1 in the Company, and to implement the corresponding increase(s) of the share capital. The warrants can be issued to employees, executive directors and board members in the Company and its subsidiaries without pre-emptive subscription rights for the Company’s shareholders. The exercise price for warrants, which are issued pursuant to the authorization, shall at a minimum correspond to the market price of the Company’s shares on the date of issuance of the warrants.

The proposal by the Board of Directors to update the Company's remuneration policy including general guidelines for incentive-based remuneration to members of the Board of Directors and Executive Management was approved by the General Meeting, and this resolution was incorporated in the Company's Articles of Association.

The proposal by the Board of Directors to authorize the Board of Directors to increase the share capital was adopted by the General Meeting, and this resolution was incorporated as new Article 6 in the Company's Articles of Association. In accordance therewith the Board of Directors is until 03 April 2024 authorized, at one or more times, to increase the share capital by cash payment up to nominally DKK 17,181,953.50 at market price by issuing new shares, each with a nominal value of DKK 0.1, with or without pre-emptive subscription rights for the Company’s shareholders.

The General Meeting granted the Board of Directors an authorization until the next annual general meeting for the Company to acquire the Company's own shares for up to 10 percent of the Company's share capital at any time, provided that the acquisition, in accordance with the Danish Companies Act Section 197, can be financed by the funds that may be distributed as ordinary dividends. The payment may not divide from the stock price at NASDAQ Copenhagen A/S with more than 10 percent at the time of purchase.

 

For more information, please contact:

 Craig A. Collard    Ira Duarte
 President & CEO  CFO
 Phone: + 1 919 591 3090  Phone: +1 919 591 3090
 Email: cac@veloxis.com  Email: idu@veloxis.com

             

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

 

 

Attachment

Veloxis_logo - Color - Screen.png

Relateret indhold
09 aug - 
Fredagens aktier: Ørsted endte i top og Novo Nordisk ta..
09 aug - 
Aktier/middag: Novo Nordisk og Ørsted ligger i toppen a..
09 aug - 
Aktier/åbning: Novo til tops i C25 - Veloxis og H+H til..
Relateret debat
17:18 - 
Nogle investorer vil da være fristet til gevinsthjemtag..
16:47 - 
Der er vel ikke noget der holder den fra at sælge ud !
16:04 - 
det er jeg ikke så sikker på ,sælger siden er ikke så s..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 aug
VELO
Da flere skribenter stadig gerne vil beholde tråden for samling af de mange vigtige informationer o..
44
15 aug
VELO
Det kunne tyde på at nogen mor modtaget receptal, der udviser netop det vi har talt om - at Envarsus..
37
20 aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
20
18 aug
VELO
Fra anden skribent i Veloxis FB gruppen: Børsen side 4, søndag den 18. august. Et uddrag fra e..
20
18 aug
VELO
'83. Det er en god kommentar, iøvrigt har jeg kontaktet DDB i fredags for at høre om de læser recept..
15
18 aug
VELO
Jeg har næppe sagt, at vi har 20 per January men et tal tættere på 17.000. Veloxis oplyser i deres ..
13
18 aug
VELO
Man har endda sat Veloxis ind på 1.pladsen 😊 Uddrag af artiklen: "De ti stærkeste og svageste..
11
19 aug
VELO
God morgen Krabask. Ja og en god morgen til jer alle...   Det var en god beslutning at fortsætte trå..
10
18 aug
VELO
Synes iøvrigt det er flot, hvis vi når de 15.500 patienter. Ifølge mit estimat når vi et nettoresult..
9
20 aug
VELO
Veloxis får 450 de-novo patienter per måned   Stigende momentum mærkes nu fra Shortage manglen   Ing..
8

Pandora-topchef køber aktier for 12,3 mio. kr.

21-08-2019 12:38:56
Pandoras topchef, Alexander Lacik, har ligesom finansdirektør Anders Boyer købt op i smykkeselskabet.Lacik har erhvervet sig knap 50.000 Pandora-aktier til en samlet pris på omtrent 12,3 mio. kr., fremgår det onsdag af en fondsbørsmeddelelse.Stykprisen, topchefen har betalt for aktierne, løber derfor op i 247,3 kr.Onsdag ved middagstid koster en Pandora-aktie 292,90 kr. på børsen i København efter..

Fiat og Renault drøner i vejret efter rygter om mulig fusion

Relaterede nyheder
21-08-2019 12:08:08
En fusion af Italien og Frankrig kan tyde på mere end bare et kulinarisk mesterværk, da investorerne onsdag middag har sat tænderne i bilaktierne for Fiat og Renault.Franske Renault drøner i vejret med 4,4 pct., og italienske Fiat følger med i svinget med en stigning på 3,8 pct., efter rygter om at en mulig fusion mellem de to bilgiganter stadig kan være på tale.Ifølge Bloomberg News fortæller ano..

Netcompany/CEO: Vi vækster inden for de lovede rammer

21-08-2019 08:38:35
Netcompanys regnskab for andet kvartal af regnskabsåret 2019 viser overordnet set, at it-virksomheden har godt styr på forretningen.Det mener selskabets administrerende direktør, André Rogaczewski.- Kort sagt må vi sige, at vi har godt styr på forretningen. Vi leverer det, vi har lovet. Vi vækster inden for de rammer, vi har lovet. Vi har ansat en masse dygtige medarbejdere, og vi har en forretnin..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/Jyske Bank: Løfter anbefaling til "køb" og hæver kursmål
2
Aktier/tendens: Pandora nærmer sig milepæl for året
3
Pandora-topchef køber aktier for 12,3 mio. kr.
4
Pandora/Sydbank: Flere forhold har givet smykkeaktien vind i sejlene
5
Aktier/middag: Pandora er "talk of the town" og stiger markant

Relaterede aktiekurser


Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. august 2019 17:39:31
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190819.1 - EUROWEB7 - 2019-08-21 17:39:31 - 2019-08-21 17:39:31 - 1 - Website: OKAY